Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use?

Table 1

Performance of CAP (M probe) to diagnose steatosis in patients with CLD, with liver biopsy as the reference method.

Author	No. of patients	Etiology	Prevalence of S ≥ 1 (%)	S ≥ 1		S ≥ 2		S = 3
				Cut-off (dB/m)	AUROC	Cut-off (dB/m)	AUROC	Cut-off (dB/m)	AUROC
Sasso [28]	615	HCV	30	222	0.80	233	0.86	290	0.88
Myers [27]	153	Mixed	65	283	0.81	—	—	—	—
De Ledinghen [25]	112	Mixed	48	215	0.84	252	0.86	296	0.93
Chan [32]	105	NAFLD	97	263	0.97	281	0.86	283	0.75
De Ledinghen [13]	440	Mixed	51.5	—	0.79	—	0.84	—	0.84
Ferraioli [26]	114	Mixed	42.6	219	0.76	296	0.82	—	—
Lupsor-Platon [33]	201	Mixed	45.3	260	0.81	285	0.82	194	0.84
Shen [34]	332	Mixed	42.5	255	0.88	283.5	0.90	293.5	0.84
De Ledinghen [35]	261	NAFLD	100	—	—	310	0.80	311	0.66
Imajo [36]	142 (10 controls)	NAFLD	83	236	0.88	279	0.73	302	0.70
Park [37]	104	NAFLD	91	261	0.85	305	0.70	312	0.73
Naveau [38]	123	NAFLD	81	298	0.81	303	0.58	326	0.37
Siddiqui [39]	393	NAFLD	95	285	0.76	311	0.70	306	0.58
Thiele [40]	269	Alcoholic liver disease	72	290-rule-in 220-rule-out	0.77	328-rule-in; 257-rule-out	0.78	339-rule-in; 286-rule-out	0.83
Shalimar [30]	219	NAFLD	93.2	285	0.96	331	0.71	348	0.75
Oeda [24]	137	NAFLD	96.3	—	—	264	0.64	289	0.69
Somda [41]	249	Severely obese	84.3	255	0.86	288	0.83	297	0.79
Eddowes [20]	450	NAFLD	88	302	0.87	331	0.77	337	0.70
Baumeler [42]	224	Mixed	62.1	258.5	0.78	282.5	0.83	307.5	0.82
Trowell [43]	217	Mixed	43	278	0.82	301	0.79	—	—
Zeng [44]	173	Liver donors	—	244	0.88	—	0.89	—	—

CAP: controlled attenuation parameter; S: steatosis; AUROC: area under the receiver operating characteristic curve; HCV: hepatitis C virus; NAFLD: nonalcoholic fatty liver disease.